173 related articles for article (PubMed ID: 36012454)
1. Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.
Sahasrabudhe SA; Terluk MR; Rudser KD; Cloyd JC; Kartha RV
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012454
[TBL] [Abstract][Full Text] [Related]
2. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy.
Ersoy M; Pişkinpaşa H
J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971
[TBL] [Abstract][Full Text] [Related]
4. Patients with Gaucher disease display systemic oxidative stress dependent on therapy status.
Kartha RV; Terluk MR; Brown R; Travis A; Mishra UR; Rudser K; Lau H; Jarnes JR; Cloyd JC; Weinreb NJ
Mol Genet Metab Rep; 2020 Dec; 25():100667. PubMed ID: 33335836
[TBL] [Abstract][Full Text] [Related]
5. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
Rosenbloom B; Balwani M; Bronstein JM; Kolodny E; Sathe S; Gwosdow AR; Taylor JS; Cole JA; Zimran A; Weinreb NJ
Blood Cells Mol Dis; 2011 Jan; 46(1):95-102. PubMed ID: 21067946
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
7. High day-to-day and diurnal variability of oxidative stress and inflammation biomarkers in people with type 2 diabetes mellitus and healthy individuals.
Mallard AR; Hollekim-Strand SM; Ingul CB; Coombes JS
Redox Rep; 2020 Dec; 25(1):64-69. PubMed ID: 32693740
[No Abstract] [Full Text] [Related]
8. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
10. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
11. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
12. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease.
Dinur T; Istaiti M; Frydman D; Becker-Cohen M; Szer J; Zimran A; Revel-Vilk S
Orphanet J Rare Dis; 2020 Oct; 15(1):284. PubMed ID: 33050940
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity.
Stein P; Yang R; Liu J; Pastores GM; Mistry PK
J Inherit Metab Dis; 2011 Apr; 34(2):429-37. PubMed ID: 21290183
[TBL] [Abstract][Full Text] [Related]
14. Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.
Machaczka M; Paucar M; Björkvall CK; Smith NJC; Cox TM; Forsgren L; Svenningsson P
Blood Cells Mol Dis; 2018 Feb; 68():86-92. PubMed ID: 27789132
[TBL] [Abstract][Full Text] [Related]
15. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials.
Elstein D; Belmatoug N; Deegan P; Göker-Alpan Ö; Hughes DA; Schwartz IVD; Weinreb N; Bonner N; Panter C; Fountain D; Lenny A; Longworth L; Miller R; Shah K; Schenk J; Sen R; Zimran A
Orphanet J Rare Dis; 2022 Jan; 17(1):9. PubMed ID: 34991656
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular diastolic dysfunction in type I Gaucher disease: an echo Doppler study.
Lo Iudice F; Barbato A; Muscariello R; Di Nardo C; de Stefano F; Sibilio M; Strazzullo P; de Simone G; Galderisi M
Echocardiography; 2015 Jun; 32(6):890-5. PubMed ID: 25250513
[TBL] [Abstract][Full Text] [Related]
18. The modulation of inflammatory parameters, Brain-derived neurotrophic factor levels and global histone H4 acetylation status in peripheral blood of patients with Gaucher disease type 1.
de Mello AS; da Silva IR; Reinaldo GP; Dorneles GP; Cé J; Lago PD; Peres A; Elsner VR; Coelho JC
Clin Biochem; 2017 Mar; 50(4-5):228-233. PubMed ID: 27865783
[TBL] [Abstract][Full Text] [Related]
19. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
Puzo J; Alfonso P; Irun P; Gervas J; Pocovi M; Giraldo P
Atherosclerosis; 2010 Apr; 209(2):515-9. PubMed ID: 19959168
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
